850465-96-2Relevant academic research and scientific papers
Structure-activity relationships of the cycloalkanol ethylamine scaffold: Discovery of selective norepinephrine reuptake inhibitors
Mahaney, Paige E.,Gavrin, Lori K.,Trybulski, Eugene J.,Stack, Gary P.,Vu, An T.,Cohn, Stephen T.,Ye, Fei,Belardi, Justin K.,Santilli, Arthur A.,Sabatucci, Joseph P.,Leiter, Jennifer,Johnston, Grace H.,Bray, Jenifer A.,Burroughs, Kevin D.,Cosmi, Scott A.,Leventhal, Liza,Koury, Elizabeth J.,Zhang, Yingru,Mugford, Cheryl A.,Ho, Douglas M.,Rosenzweig-Lipson, Sharon J.,Platt, Brian,Smith, Valerie A.,Deecher, Darlene C.
experimental part, p. 4038 - 4049 (2009/05/07)
Further exploration of the cycloalkanol ethylamine scaffold, of which venlafaxine (1) is a member, was undertaken to develop novel and selective norepinephrine reuptake inhibitors (NRIs) for evaluation in a variety of predictive animal models. These effor
PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE
-
Page/Page column 38, (2008/06/13)
The present invention is directed to phenylpiperazine cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vas
